乳腺浸润性小叶癌组织中miR-211-5p、SETBP1的表达及其意义

摘要
图/表
参考文献(27)
相关文章 (1)

全文: PDF (536 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的检测乳腺浸润性小叶癌（ILC）组织中与miR-211-5p，SET结合蛋白1（SETBP1）的表达情况，并探讨两者在ILC中表达的临床意义。方法收集2019年1月至2020年9月海南医学院第一附属医院诊治的82例女性ILC患者的临床病理资料。应用荧光定量PCR检测癌组织和癌旁组织中miR-211-5p、SETBP1的表达水平；分析miR-211-5p、SETBP1的表达与ILC患者临床病理特征的关系；采用Pearson线性相关分析miR-211-5p与SETBP1在ILC中表达的相关性。采用生物信息学软件预测miR-211-5p与SETBP1的结合位点。结果 ILC中miR-211-5p的表达低于癌旁组织，差异有统计学意义（P ＜ 0.05）。ILC中SETBP1的表达高于癌旁组织，差异有统计学意义（P ＜ 0.05）。与肿瘤TNM分期Ⅰ～Ⅱ期ILC癌组织比较，肿瘤分期Ⅲ～Ⅳ期的ILC癌组织中miR-211-5p表达显著较低，而SETBP1的表达显著较高（P ＜ 0.05）。与无腋淋巴转移ILC癌组织比较，伴腋淋巴转移的ILC癌组织中miR-211-5p表达显著较低，而SETBP1的表达显著较高（P ＜ 0.05）。ILC癌组织中miR-211-5p与SETBP1的表达呈负相关（r = -0.573，P ＜ 0.05）。生物信息学软件预测SETBP1的3’UTR区第374至381个碱基处存在与miR-211-5p潜在的互补结合位点。结论 miR-211-5p在ILC癌组织中表达降低，SETBP1在ILC癌组织中表达升高，miR-211-5p、SETBP1的表达均与乳腺癌患者的肿瘤分期及腋淋巴结转移相关，共同参与ILC的进展，可能是ILC的诊断治疗靶点。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	翁向前1 王叶凌1 林冰1 张爽1 苏俊2

关键词 ：乳腺浸润性小叶癌, miR-211-5p, SET结合蛋白1, 临床病理参数

Abstract：Objective To detect the expression of miR-211-5p and SET binding protein 1 (SETBP1) in the tissue of infiltrating lobular carcinoma (ILC) of the breast, and to explore the clinical significance of their expression in ILC. Methods The clinicopathological data of 82 female patients with ILC treated in the First Affiliated Hospital of Hainan Medical University from January 2019 to September 2020 were collected. Fluorescence quantitative PCR was used to detect the expression levels of miR-211-5p and SETBP1 in cancer tissues and adjacent tissues. The relationship between the expression of miR-211-5p and SETBP1 and the clinicopathological features of ILC patients was analyzed. Pearson linear correlation was used to analyze the correlation between miR-211-5p and SETBP1 expression in ILC. Bioinformatics software was used to predict the binding sites of miR-211-5p and SETBP1. Results The expression of miR-211-5p in ILC was lower than that in adjacent tissues, and the difference was statistically significant (P ＜ 0.05). The expression of SETBP1 in ILC was higher than that in adjacent tissues, and the difference was statistically significant (P ＜ 0.05). Compared with tumor TNM stage Ⅰ to Ⅱ ILC cancer tissues, miR-211-5p expression was significantly lower and SETBP1 expression was significantly higher in tumor TNM stage Ⅲ to Ⅳ ILC cancer tissues (P ＜ 0.05). Compared with ILC cancer tissues without axillary metastasis, miR-211-5p expression was significantly lower in ILC cancer tissues with axillary metastasis, while SETBP1 expression was significantly higher (P ＜ 0.05). The expression of miR-211-5p was negatively correlated with SETBP1 in ILC carcinoma tissues (r = -0.573, P < 0.05). Bioinformatics software predicted the existence of potential complementary binding sites with miR-211-5p at bases 374 to 381 in the 3’UTR region of SETBP1. Conclusion The expression of miR-211-5p is decreased in ILC cancer tissues, and SETBP1 is increased in ILC cancer tissues. The expressions of miR-211-5p and SETBP1 are correlated with tumor stage and axillary lymph node metastasis in breast cancer patients, and they are both involved in the progression of ILC, which may be diagnostic and therapeutic targets of ILC.

Key words： Infiltrating lobular carcinoma of the breast miR-211-5p SET binding protein 1 Clinicopathological parameters

基金资助:海南省医药卫生科研项目（2001320675A2008）。

通讯作者: 张爽（1981.12-），女，硕士；研究方向：肿瘤放化疗。

引用本文:

翁向前1 王叶凌1 林冰1 张爽1 苏俊2. 乳腺浸润性小叶癌组织中miR-211-5p、SETBP1的表达及其意义[J]. 中国医药导报, 2021, 18(32): 108-112.
WENG Xiangqian1 WANG Yeling1 LIN Bing1 ZHANG Shuang1 SU Jun2. Expression and significance of miR-211-5p and SETBP1 in the tissue of infiltrating lobular carcinoma of the breast#br#. 中国医药导报, 2021, 18(32): 108-112.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I32/108

[1] Miller KD，Nogueira L，Mariotto AB，et al. Cancer treatment and survivorship statistics，2019 [J]. CA Cancer J Clin，2019，69（5）：363-385.
[2] 樊哲.保乳术治疗早期乳腺癌临床疗效及对患者生活质量的影响[J].山东医药，2018，58（2）：80-82.
[3] Daveri E，Vergani E，Shahaj E，et al. microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy [J]. Front Immunol，2020，11（4）：1214-1222.
[4] 董超，黄远丽，徐正丰.miR-25在乳腺癌组织、细胞的表达及对细胞增殖的影响[J].山东医药，2018，58（9）：31-33.
[5] Wang K，Jin W，Jin P，et al. miR-211-5p Suppresses Met-astatic Behavior by Targeting SNAI1 in Renal Cancer [J]. Mol Cancer Res，2017，15（4）：448-456.
[6] Bai Y，Li X. hsa_circ_0008285 Facilitates the Progression of Cervical Cancer by Targeting miR-211-5p/SOX4 Axis [J]. Cancer Manag Res，2020，12（4）：3927-3936.
[7] 连芸，钱思轩，黄佳瑜，等.老年急性髓系白血病基因突变及临床意义[J].临床血液学杂志，2018，31（1）：14-18.
[8] Albano F，Anelli L，Zagaria A，et al. SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia [J]. J Hematol Oncol，2012，5（4）：48-55.
[9] Hortobagyi GN，Connolly JL，Edge SB，et al. AJCC Cancer staging manual. 8 [M]. New York：Springer International Publishing，2016.
[10] 宋宛芝，高晋南，杨海波.乳腺癌的流行状况及发病特征[J].中国药物与临床，2017，17（2）：228-229.
[11] 祝淑钗，韩春.从乳腺癌发病变化看我国恶性肿瘤的防控重点[J].疑难病杂志，2020，19（11）：1081-1083，1090.
[12] 任玉琳，张丽，佟仲生.不同激素状态的HER2阳性晚期乳腺癌复发转移特征及生存分析[J].肿瘤防治研究，2019，46（1）：43-50.
[13] 周桂荣，苏国森，湛建伟，等.新辅助化疗+手术对不同分子亚型乳腺癌预后及影响因素分析[J].疑难病杂志，2019，18（8）：821-826.
[14] 郭凤军，邹颖刚，李丹，等.微小RNA-92与恶性肿瘤关系的研究进展[J].中国实验诊断学，2018，22（7）：1288-1290.
[15] Liu S，Wang H，Mu J，et al. miR-211-5p contributes to chondrocyte differentiation by suppressing Fibulin-4 expression to play a role in osteoarthritis [J]. J Biochem，2019，166（6）：495-502.
[16] Quan J，Pan X，He T，et al. Tumor suppressor miR-211-5p is associated with cellular migration，proliferation and apoptosis in renal cell carcinoma [J]. Exp Ther Med，2018，15（4）：4019-4028.
[17] Liu S，Wang H，Mu J，et al. miRNA-211 triggers an autophagy-dependent apoptosis in cervical cancer cells： regulation of Bcl-2 [J]. Naunyn Schmiedebergs Arch Pharmacol，2020，393（3）：359-370.
[18] Deng Y，Wei Z，Huang M，et al. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p [J]. J Cell Mol Med，2020，24（2）：1848-1865.
[19] Zhang S，Ma H，Zhang D，et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling [J]. Cell Death Dis，2018，9（7）：742-759.
[20] Fiore D，Cappelli LV，Zumbo P，et al. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries [J]. Cancers（Basel），2020，12（6）：1603-1610.
[21] Eder-Azanzal L，Hurtado C，Navarro-Herrera D，et al. Analysis of genes encoding epigenetic regulators in myeloproliferative neoplasms：Coexistence of a novel SETBP1 mutation in a patient with a p.V617F JAK2 positive myelofibrosis [J]. Mol Clin Oncol，2019，10（6）：639-643.
[22] Yang W，Su Y，Hou C，et al. SETDB1 induces epithelial mesenchymal transition in breast carcinoma by directly binding with Snail promoter [J]. Oncol Rep，2019，41（2）：1284-1292.
[23] Cao N，Yu Y，Zhu H，et al. SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression [J]. Cell Death Dis，2020，11（5）：351-362.
[24] Ryu Ty，Kim K，Kim Sk，et al. SETDB1 regulates SMAD7 expression for breast cancer metastasis [J]. BMB Rep，2019，52（2）：139-144.
[25] Zhang Y，Huang J，Li Q，et al. Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma [J]. BMC Cancer，2018，18（1）：539.
[26] Chen LL，Zhang ZJ，Yi ZB，et al. MicroRNA-211-5p suppresses tumour cell proliferation，invasion，migration and metastasis in triple-negative breast cancer by directly targeting SETBP1 [J]. Br J Cancer，2017，117（1）：78-88.
[27] Vishwakarma BA，Nguyen N，Makishima H，et al. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development [J]. Leu-kemia，2016，30（1）：200-208.